Background: To determine the prevalence and clinicopathological features of ROS1 fusions in Chinese patients with non-small-cell lung cancer (NSCLC).
introduction
Lung cancer is the most common malignant tumor and the leading cause of cancer death worldwide, with ∼1.6 million new cases and ∼1.38 million deaths annually [1, 2] . With the identification of oncogenic drivers, small molecular tyrosine kinase inhibitors have been shown to be highly effective in patients with NSCLC expressing corresponding oncogenic drivers [3] [4] [5] [6] [7] . Like EGFR mutation [3, 4, 8] and EML4-ALK fusions [9] [10] [11] , ROS1 fusions are shown to be essential for lung cancer development and serve as an effective therapeutic target of crizotinib (PF02341066, Xalkori, Pfizer) in subgroups of populations [12, 13] .
ROS1 (also known as ROS, MCF3 or c-ros-1) is a protooncogene highly expressed in a variety of tumor cell lines [14] , and a member of sevenless subfamily of tyrosine kinase insulin receptor genes. ROS1 protein is a type I integral membrane protein with tyrosine kinase activity and may serve as a growth or differentiation factor receptor [15] . The ROS1 rearrangement rendering a constitutively active tyrosine kinase was first discovered in glioblastoma in 1987 [14] , then in NSCLC in 2007 [16] , and in cholangiocarcinoma and ovarian cancer in 2011 [17, 18] . The patterns of ROS1 fusion identified in lung cancer to date include SLC34A2-ROS1, CD74-ROS1, TPM3-ROS1, SDC4-ROS1, EZR-ROS1, LRIG3-ROS1, FIG-ROS1, KDELR2-ROS1 and CCDC6-ROS1, with overall prevalence of 0.9-2.6% in NSCLC [6, 12, 13, [19] [20] [21] [22] . A study found ROS1 fusion-positive patients tended to be younger never smokers with a histologic diagnosis of adenocarcinoma [6] . However, there is no evidence strong enough to support this finding as far due to a very low frequency of ROS1 fusions in NSCLC. Additionally, Davies et al. identified ROS1 fusions in squamous cell carcinoma histology for the first time [13] .
Moreover, only two of five ROS1 fusion-positive patients were never smokers. Therefore, the definitive clinicopathological features associated with the ROS1 fusion status remain elusive, although some previous studies have investigated the frequency and clinical features of ROS1 fusions.
Up to date, there were still some problems in the clinical application of fluorescence in situ hybridization (FISH), including high costs, difficulty in interpretation and expertise required, although FISH is the unique diagnostic approach approved to screen for ALK rearrangement in NSCLC by FDA. Besides that, immunohistochemistry (IHC) is a cheap and widely used assay for fusion proteins; however, there has been no preferred antibody for identification of ROS1 fusion proteins to date. A large study Lungscape project conducted in Europe screened for ALK rearrangement using IHC and demonstrated a prevalence of ALK rearrangement of 7.3% [23] . Although a high concordance between ALK IHC 3+ and FISHpositive results has been demonstrated, FISH sensitivity was only 36.7% in ALK IHC 1+, 2+ and 3+ samples (data present in the 37th ESMO). In addition to FISH and IHC, multiplex RT-PCR is an alternative method used to identify gene fusion in NSCLC. A previous Chinese study [24] detected two ROS1 fusion-positive cases from 202 East Asian never smokers with lung adenocaricnoma (LADC) using RT-PCR and sequencing, with a prevalence of 1%. However, the study just designed primers for CD74-ROS1 and SLC34A2-ROS1 at that time, so it is very possible that some ROS1-positive patients with other fusion patterns were missed. The RT-PCR assay is highly sensitive, relatively cheap and easily widespread, and can determine specific fusion partners, although it cannot identify unknown variants. We identified eight ROS1 fusion-positive cases from 392 NSCLC patients using multiplex RT-PCR, with a prevalence of 2.0%. We characterized all ROS1 fusionpositive cases to define the most likely population to benefit from specific targeted therapy. . All FFPE tissue sections were reviewed by pathologists for confirmation of histology and assessment of tumor content. All clinical data were obtained from inpatient/outpatient medical records. Patients were classified into three groups according to the smoking status: never (0 pack year), light (<10 pack years), and smokers (≥10 pack years, including former smokers and current smokers). Survival analysis was carried out in patients who received at least one follow-up phone call or visit. All enrolled patients met the following inclusion criteria: written informed consent; aged ≥18 years; NSCLC histologically confirmed; sufficient FFPE tissue available for ROS1 fusion screening and validation; the demographic data, including age, gender, smoking status, histological type and disease stage, were available for analysis. Patients did not receive pre-operative systemic or radiation therapy. This study was approved by the institutional review boards of the Shanghai Pulmonary Hospital.
RNA extraction and reverse transcription
Total RNA was extracted from 3 to 4 sections of 3 μm-thick FFPE tissue using a RNeasy FFPE kit (QIAGEN, Cat. no.73504). Then, total RNA was subject to reverse transcription using an AmoyDx® ROS1 fusion gene detection kit (Amoy Diagnostics Co., Ltd, Xiamen, China). Total amount of RNA should be within 0.1-5 μg. Reverse transcription conditions were as follows: 42°C, 1 h; 95°C, 5 min. The resulting complementary DNA (cDNA) solutions are used for a multiplex RT-PCR.
multiplex RT-PCR and direct sequencing
To rapidly and high-efficiently identify ROS1 fusions using small amounts of RNA extracted from archival FFPE sections, we used a multiplex RT-PCR to screen for these fusions in this study. The patterns of ROS1 fusions screened in this study are shown in Table 1 . All multiplex RT-PCRs were carried out using a Stratagene Mx3000P real-time PCR system (Strategene, CA) with an AmoyDx® ROS1 fusion gene detection kit (Amoy Diagnostics Co., Ltd, Xiamen, China). An internal reference gene (β-actin) and ROS1-rearranged DNA were used as control. The PCR conditions were as follows: one cycle of 95°C for 5 min; 15 cycles of denaturation at 95°C for 25 s, annealing at 64°C for 20 s and elongation at 72°C for 20 s; 31 cycles of 93°C for 25 s, 60°C for 35 s (data collection) and 72°C for 20 s. All fusionpositive samples were validated using direct sequencing. The sequence primers used in this study are shown in supplementary Table S1 , available at Annals of Oncology online. The PCR conditions for sequence primers were as follows: one cycle of 95°C for 5 min, followed by 50 cycles of denaturation at 90°C for 30 s, annealing at 50°C for 30 s and elongation at 72°C for 40 s, and the last cycle was extended by a 7 min elongation at 72°C.
statistical analysis
Categorical variables were compared using Fisher's exact test, and continuous variables were compared using the Mann-Whitney U test. The survival curve was plotted and median overall survival was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were carried out using the Cox proportional hazard model. Overall survival was defined as the time from the date of resection or biopsy to the date of death. Patients alive or lost to follow-up were censored at the date of last follow-up. A log-rank test was used to compare the survival curves between ROS1-positive and ROS1-negative groups. The two-sided significance level was set at P < 0.05. All data were analyzed using the Statistical Package for the Social Sciences Version 17.0 Software (SPSS). Table 2 ). The ROS1 fusion status was evaluable in archival FFPE tissue sections from all patients.
ROS1 fusions
Eight out of 392 (2.0%) cases were found positive for the ROS1 fusions by a multiplex RT-PCR, which were confirmed by direct sequencing. Among them, SLC34A2-ROS1 fusion was found in four cases, CD74-ROS1 fusion in three cases and SDC4-ROS1 fusion in one case. The fusion pattern and clinicopathological features of all ROS1 fusion-positive patients are shown in Table 3 . Notably, a SLC34A2-ROS1 fusionpositive case was validated to express two variants, S13(del); R32 and S13(del);R34. In the cDNA of these two variants, nucleotide position 568 of SLC34A2 exon 13 is fused to ROS1 exons 32 and 34, respectively. The validated sequencing results of ROS1 fusion-positive cases are shown in Figure 1 .
clinicopathological features of ROS1-positive patients
Of eight ROS1 fusion-positive patients, seven had adenocarcinoma, and one had adenosquamous carcinoma histology. Seven of 231 patients with LADC were positive for ROS1 fusions, accounting for 3.03%. ROS1 fusions appeared to be more common in adenocarcinoma histology. The median age at diagnosis was 64 years. The ratio of female to male and never smoker to smokers in a ROS1 fusion-positive group was 5:3. There was no statistically significant difference in age (P = 0.866), sex (P = 0.479), smoking history (P = 1.0), histological type (P = 0.148) and pathological stage (P = 0.475) between ROS1 fusion-positive and ROS1 fusion-negative patients.
clinical outcomes ROS1-negative patients had a significantly longer overall survival than ROS1-positive patients, with a P value of 0.041. The survival curve is shown in Figure 2 . Univariate analysis identified age <65 years (P = 0.011), female (P = 0.023), low pathological stage (P < 0.001) and ROS1 fusion-negative status (P = 0.047) as being significantly associated with longer survival. Additionally, never/light-smoking history showed a strong trend toward better overall survival, without reaching statistical significance (P = 0.072). Multivariate analysis identified low pathological stage (P < 0.001) as being the strongest independent prognostic factor for better survival.
Other independent factors affecting survival were age <65 years (P = 0.004) and ROS1 fusion-negative status (P = 0.01) ( Table 4) .
discussion
In this study, we identified eight patients with NSCLC positive for ROS1 fusions by multiplex RT-PCR using primers for 13 known variants, with the prevalence of 2.0%. Of these ROS1 fusion-positive patients, seven had adenocarcinoma and one had adenosquamous carcinoma histology. Analysis indicated original articles Annals of Oncology that no specific clinicopathological feature was significantly associated with the ROS1 fusion status. ROS1 fusion-negative patients had a significantly better overall survival than those harboring ROS1 fusions, with a P value of 0.04.
We screened for known ROS1 fusions, except FIG-ROS1 , KDELR2-ROS1 and CCDC6-ROS1, in NSCLC using a multiplex RT-PCR, and identified SLC34A2-ROS1 fusion in four cases, CD74-ROS1 fusion in three cases and SDC4-ROS1 fusion in one case. The former two appeared to occur in NSCLC with higher frequency when compared with other fusion patterns. A total of nine known fusion partners for ROS1 were identified in NSCLC at present. Among them, SLC34A2 and CD74 were the first to be found and the most investigated partners as far. Then, Takeuchi et al. identified additional four fusion partners for ROS1 in NSCLC: TPM3, SDC4, EZR and LRIG3 [12] . Lately, FIG-ROS1, KDELR2-ROS1 and CCDC6-ROS1 fusions were originally described in NSCLC by Rimkunas et al., Govindan et al. and Seo et al., respectively [20] [21] [22] . Moreover, Davies et al. observed a more potent inhibition of crizotinib in Ba/F3 cells transduced with SDC4-ROS1 (SD2;R32) compared with HCC78 cells (a NSCLC cell line harboring SLC34A2-ROS1), with the IC50 values of 31 and 775 nmol/l, respectively. The difference in sensitivity to crizotinib between SDC4-ROS1 expressing Ba/F3 cells and HCC78 cells may be partially due to fusion partner identity. Besides that, the scholars also believed that reduced sensitivity to ROS1 inhibitor may be partially attributed to EGFR bypass activation [13] . It is very important to be aware of the discrepancy in frequency and sensitivity to ALK/ROS1 inhibitors between different ROS1 fusion patterns and is very essential to determine the definitive patterns of ROS1 fusions in clinical practice. The finding from this study is consistent Figure 1 . The variants of ROS1 fusions identified by a multiplex RT-PCR were validated by direct sequencing. (A). S4;R32 in three cases, (B) S13del;R32 and (E) S13del;R34 in one case, (C) C6;R32 in one case, (D) SD2;R32 in one case, and (F) C6;R34 in two cases.
Annals of Oncology original articles
with most previous studies [6, 13, 20] , although we cannot draw a hasty conclusion for the frequency and identity of each fusion pattern on the basis of such small number of ROS1 fusion-positive cases. ROS1 fusions were shown to occur in eight NSCLC patients in our study, with the prevalence of 2.0% which was slightly higher than some previous reports. Bergethon et al. identified ROS1 fusion in 1.7% (18 out of 1073) of the NSCLC patients using FISH. Of 14 ROS1 fusion-positive cases with sufficient tissue, 5 were found to harbor CD74-ROS1, 1 to harbor SLC34A2-ROS1, and 8 were still unknown by RT-PCR with a panel of PCR primers including CD74-ROS1 (C6;R32/34) and SLC34A2-ROS1 (S4;R32/34) [6] . Then, Takeuchi et al. identified 13 ROS1 fusion-positive cases from 1476 NSCLC patients using FISH, with the prevalence of 0.9% (including CD74-ROS1 in three cases, SLC34A2-ROS1 in one, SDC4-ROS1 in three, TPM3-ROS1 in two, EZR-ROS1 in two, LRIG3-ROS1 in one and an unknown pattern in one) [12] . Similarly, 1.2% (5 out of 428) of evaluable NSCLC samples were found using FISH in a recent study by Davies et al. [13] . Recently, ROS1 fusions were detected in 1.6% (9 out of 556) of Chinese patients with NSCLC using IHC by Rimkunas et al. [20] . There seems to be no significant difference in ROS1 fusion expression between different ethnicities. Accordingly, we consider that the slightly high frequency of ROS1 fusions in our study is at least partially attributed to different screening methods. Moreover, the definitive fusion patterns of ROS1 cannot be determined using FISH. In our study, all ROS1 fusion-positive samples identified by a RT-PCR were validated by direct sequencing. Therefore, we believe that the RT-PCR alone was capable of detecting samples with ROS1 fusions and could be routinely applied in clinical practice.
As opposed to a previous study by Bergethon et al., there is no statistically significant difference in age, smoking history and pathological stage in this study. Moreover, ROS1 fusionnegative patients had a significantly better survival than ROS1 fusion-positive patients (53.9 versus 32.2 months, P = 0.041) on survival analysis. A multivariate analysis identified three independent predictors for better prognosis: age <65 years, low pathological stage and ROS1-negative status. Takeuchi et al. demonstrated that negative kinase-fusion status was one of the independent predictors of poor prognosis on a multivariate analysis of 1116 patients with LADC containing 71 fusionpositive adenocarcinomas. However, only 13 of 71 harbored ROS1 fusions and all patients assessed had adenocarcinoma histology [12] . Besides that, a study conducted by Lee et al. found that 22% of NSCLC were positive for ROS1 expression and ROS1 expression was an independent factor for worse prognosis in patients with stage I adenocarcinoma (HR: 1.942, 95% CI: 1.164-3.239, P = 0.011) on a multivariate analysis. Moreover, compared with primary NSCLC, ROS1 expression occurred significantly more frequent in recurrent lesions (38% versus 19%, P < 0.001) [25] . Although we consider that ROS1 fusions may be associated with poor survival in NSCLC patients, the low frequency of ROS1 fusion-positive patients may have a potential impact on the statistical evaluation of this study. Therefore, the association between ROS1 fusions and poor prognosis still needs a further study with a large sample size to confirm.
Of interest, we also identified ROS1 fusions in 2.7% (1 out of 37) of patient with adenosquamous carcinoma. The frequency of ROS1 fusions in patients with adenosquamous carcinoma here may not reflect the prevalence in general population of NSCLC patients based on a small number of ROS1 fusionpositive samples. Besides that, no case from 119 patients with squamous cell carcinoma histology was found to harbor ROS1 fusions in our study. A recent study by the Cancer Genome Atlas Research Network profiled 178 lung squamous cell carcinomas and identified a large number and variety of DNA alterations, including a mean of 165 genomic rearrangements per tumor. However, no recurrent rearrangement predicted to generate fusion proteins was detected [26] . In fact, gene fusions, including EML4-ALK and RET fusions (data not shown), have been identified in lung squamous cell carcinoma. Additionally, two ROS1 fusion-positive patients with squamous cell carcinoma were identified in 428 assessable NSCLC patients by Davies et al. [13] . We also have demonstrated that ROS1 fusions do not occur exclusively in LADC. However, for the cases with adenosquamous carcinoma histology, we cannot determine whether the occurrence of ROS1 fusions is attributed to the presence of the adenocarcinoma component or squamous component. No ROS1 fusion-positive sample with squamous cell carcinoma identified may be due to the relatively small number of samples with squamous cell carcinoma histology.
In conclusion, the prevalence of ROS1 fusions in NSCLC is low, even in Chinese patients. The ROS1-negative status is one of the three independent factors that are indicators of better prognosis. Additionally, with further research on fusion gene, the fusion patterns of ROS1 become increasingly complex. However, do all patterns of ROS1 fusions identified in NSCLC serve as an oncogenic driver and have a similar sensitivity to ALK/ROS1 inhibitors? There is no definitive answer so far. Given the demonstrated good clinical efficacy of crizotinib in the treatment of NSCLC harboring ROS1 fusions, our study provides new insights into the definition of the NSCLC population most likely to benefit from crizotinib in the absence of a standard diagnostic approach for NSCLC harboring ROS1 fusions at present. An expanded study on ROS1 fusions in Chinese NSCLC patients is ongoing.
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